ProStrakan Group plc company specializes in those areas, but also focuses on therapies for women's health and issues relating to the ageing male. ProStrakan's marketed products include brain tumor treatment Bélustine and bone therapy Adcal. Products in development include therapies to treat alopecia and hypogonadism. ProStrakan markets its products to more than 10 countries in the EU, and has applied for FDA approval of pain medication Abstral in the US. ProStrakan company was founded as Strakan in 1995 by Chairman Harry Stratford and changed its name to ProStrakan when it merged with ProSkelia. Warbug Pincus and Aventis Pharma each hold majority shares in the company.

Intarcia Therapeutics (formerly BioMedicines) sniffs out the competition for its drugs. The development-stage company identifies potential drug candidates in other firms' pipelines, then buys the rights to products it believes can be developed more efficiently or can be effective in treating different indications. Lead drug candidate Atamestane, acquired from Schering AG (now Bayer Schering ), is in clinical trials as a potential treatment for metastatic breast cancer. The company's pipeline also includes omega interferon (purchased from Boehringer Ingelheim), which is being developed to treat hepatitis C; and Biomed 101 (from G.D. Searle), which may have applications for melanoma and kidney cancer.

The Wellcome Trust Sanger Institute (Sanger Institute) is a leading research center dedicated to analyzing and understanding genomics. Best known for its work on the Human Genome Project (the institute is responsible for sequencing one-third of the human genome), the Sanger Institute is applying genomics to the study of organisms that cause diseases such as malaria, typhoid, and tuberculosis. The institute was founded in 1993 by the Wellcome Trust and the Medical Research Council, and has been funded by a $430 million grant from the Wellcome Trust since 2001.

Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate dutogliptin is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and certain types of cancer. The biotechnology firm's drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. The company is owned by a number of private investors.

Mediatech, Inc. company develops, manufactures, and distributes molecular biology and cell culture reagents used by research labs. Its customers include pharmaceutical companies, government agencies, and academic institutions. Mediatech's products are sold under the cellgro and Insectagro brands, and include cell culture media, reagents, salt solutions, antibiotics, and bioprocess collection containers. The company also provides custom formulation and contract manufacturing services. Its products are sold in the US through its own sales force and through third-party distributors internationally. Mediatech was formed in 1984.

Roche Diagnostics Corporation company was founded in 1998 and is headquartered in Indianapolis, Indiana. Roche Diagnostics Corporation operates as a subsidiary of Roche Holding AG. Roche Diagnostics Corporation offers diagnostic tests and systems. The company operates in the diagnostic areas of diabetes care, centralized diagnostics, applied science, molecular diagnostics, and point-of-care diagnostics. Its products include diagnostics tools that test for congestive heart failure, HIV, Hepatitis B and C, fertility, and diabetes diseases. The company supplies its products to researchers, physicians, patients, hospitals, and laboratories. It has facilities in Indiana, New Jersey, South Carolina, Colorado, New Hampshire, Puerto Rico, and California, as well as locations in Canada.

Indiana Botanic Gardens makes, markets, and sells herbal supplements, cosmetics, and other natural products.Its Botanic Choice and Botanic Spa lines feature such exotic ingredients as hoodia (an African desert plant), Indian Water Hyssop, and emu oil. In all, it sells about 1,700 items to customers throughout the US and abroad. The company does most of its business through its mail-order catalogue and online retail site; it also operates a retail store and offers wholesale sales for other retailers. Joseph E. Meyer, author of the classic reference book The Herbalist, founded Indiana Botanic Gardens in 1910. His great-grandson Tim Cleland is the company's president.

Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

MonoSol Rx, Inc. company develops thin film versions (about the size of a postage stamp) of new and existing prescription and over-the-counter drugs for colds, nausea, pain, and other ailments. MonoSol creates its thin film products, which are easier to take than tablets or capsules, primarily through partnerships with other pharmaceutical companies. Brands of current drug candidates for its thin film strips include Ambien, a sleep aid, and Lexapro, an anti-depressant. The company has a manufacturing facility in Portage, Indiana, and focuses on creating products for US, Europe, and Asia/Pacific markets.

PureTek Corporation company, founded in 1991 by CEO Barry Pressman, manufactures a variety of bulk and private label pharmaceutical, nutritional, and personal care products for retail chain stores and branded drug companies throughout the US. PureTek's nutritional and pharmaceutical products are offered through its Breath Relief, D-CARE, PharmaPure, and Pharmaflex brands. Its personal care items are supplied through the Dermectin and Body Essence lines. PureTek has the ability to produce pharmaceutical and nutritional delivery systems encompassing tablets, capsules and liquids, as well as large-batch capacity for personal care liquids, lotions, creams, and oils.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.